The IMID Forum

EULAR 2022 Preview Podcast by The Immune-Mediated Inflammatory Disease Forum

Join Prof Iain McInnes as he reviews two interesting papers published in May 2022!

The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease.

Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professors Tina Vilsbøll and Naveed Sattar as they discuss two papers from the world of cardiometabolic disease research.

The first compares the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed T2D.

The second assesses the efficacy of semaglutide among an east Asian population of adults with overweight or obesity. Each month, two of our steering committee members discuss the latest research in cardiometabolic diseases. Everything discussed is available in a more detailed slide format in the publications section at cardiometabolicforum.com.

Professor Peter Taylor, from the University of Oxford in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Peter Taylor discusses pain control in early RA treated with baricitinib monotherapy.

Prof Iain McInnes reviews three papers this month!. The first – from Taylor et al – looks at pain control in early RA treated with baricitinib, the second investigates the immunogenicity of pneumococcal vaccination in patients with RA receiving upadacitinib and MTX, and the third paper is a perspective on regulatory changes in the wake of the ORAL SURVEILLANCE results. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Rüdiger Müller discusses his paper on the impact of switching tofacitinib dose in patients with RA.

Discussing Rheumatology: March 2022 by The Immune-Mediated Inflammatory Disease Forum

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.

Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

ACR1540 Ana Rita Cruz - Machado by The Immune-Mediated Inflammatory Disease Forum